The Archer® FusionPlex® Acute Lymphoblastic Leukemia (ALL) Kit is a targeted next-generation sequencing assay to detect and identify fusions, point mutations and expression levels in 81 genes associated with Acute Lymphoblastic Leukemia, including all recurrent Ph-Like ALL fusion events. The kit uses Archer’s proprietary Anchored Multiplex PCR (AMP™)-based enrichment to detect fusions of all target genes in a single sequencing assay, even without prior knowledge of fusion partners or breakpoints.
For Research Use Only. Not for use in diagnostic procedures.
# of GSP2s
Input nucleic acid required*
Recommended # of reads
Unique molecular on-target %
Blood, fresh frozen, FFPE
*Input recommendations for FFPE samples vary depending on Archer Preseq® RNA QC score; 50ng input recommended in absence of PreSeq screening
Need to modify your panel?
Add any of our wet lab-validated designs to this panel with Archer Assay Designer to build an assay that fits your exact requirements.
The FusionPlex ALL kit includes targets found in Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL), which is characterized by modifications in lymphoid transcription factor genes, poor outcomes, and a gene-expression profile similar to that of BCR-ABL1 ALL. Recent clinical and xenograft studies have revealed that the Ph-like ALL gene expression profile includes multiple genomic alterations, which are listed in the table below.
|Kinase||Number of gene partners||Fusion partner genes|
|ABL1||7||ETV6, NUP214, RCSD1, RANBP2, SNX2, ZMIZ1|
|ABL2||3||PAG1, RCSD1, ZC3HAV1|
|PDGFRB||4||EBF1, SSBP2, TNIP1, ZEB2|
|JAK2||10||ATF7IP, BCR, EBF1, ETV6, PAX5, PPFIBP1, SSBP2, STRN3, TERF2, TPR|
*FusionPlex ALL Kit will only detect an EPOR truncation
2477 55th Street, Suite 202
Boulder, CO 80301